Tag: genomics
-
Report: More Biotech Regulations Needed, and Soon
A new report from the National Academies calls for a more robust and responsive regulatory system to handle an anticipated flood of biotechnology products.
-
Precision Medicine, “My Hope for the Future”
A meeting on Capitol Hill in Washington, D.C. today heard about one person’s struggle with cystic fibrosis and her hope for precision medicine to provide a cure.
-
Messenger RNA Engineered to Produce Antibodies
Academic and industry researchers demonstrated production of therapeutic antibodies inside cells of lab mice, offering a simpler and lower-cost alternative to monoclonal antibodies.
-
Cancer Blood Test Company Raises $65M in Early Funds
Freenome, a company applying machine learning to analysis of liquid biopsies, is raising $65 million in its first round of venture financing.
-
Test of Nasal Skin Cells Found to Detect Lung Cancer
A diagnostic test analyzing the genes in skin cells from nasal passages can detect lung cancer, and the absence of cancer, as accurately as more invasive samples from the airways.
-
Duchenne Gene-Editing Company Launched, Raising $5M
A biotechnology start-up is applying a process for editing-out disease-causing mutations to correct the inherited disorder Duchenne muscular dystrophy.
-
Genome Editing Builds Viral Disease Resistance in Pigs
Veterinary researchers used Crispr-Cas9, an emerging genome editing technique, to produce pigs with cells resistant to a common viral disease affecting commercial herds.
-
Patent Issued for Peptides in Diabetes Gene Therapy
A U.S. patent was issued today for synthetic peptides that support gene therapies developed to treat type 2 diabetes and heart failure.
-
Patent Office Decides for Broad and Editas in Crispr Case
The U.S. Patent and Trademark Office decided that the gene editing processes developed by Broad Institute and licensed to Editas Medicine do not interfere with techniques for genome editing created by University of California at Berkeley.
-
Biotech Group Withholds Support for Germline Trial Report
A biotechnology industry association in the U.S. says its members are not ready to support recommendations in a new report permitting future clinical studies of genome editing for inheritable disease-causing traits.